Overview

Mylan Insulin Aspart Study

Status:
Completed

Trial end date:
2020-01-17

Target enrollment:

Participant gender:

Summary

The aim of this phase III trial is to demonstrate the equivalence in the safety and efficacy profile between MYL-1601D and NovoLog® in patients with T1DM.

Phase:

Phase 3

Details

Lead Sponsor:

Mylan Inc.

Collaborator:

Mylan GmbH

Treatments:

Insulin Aspart